| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802650001028 | 265000102 | INSPRA F.C.TAB 25MG/TAB BT x 20 (σε Blisters PVC/AL) (σε Blisters PVC/AL) | 10.44 | 10.95 | 15.09 |
| 05/2018 | 2802650002025 | 265000202 | INSPRA F.C.TAB 50MG/TAB BTx20 (σε Blisters PVC/AL) (σε Blisters PVC/AL) | 10.44 | 10.95 | 15.09 |
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
Eplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.
The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.
The absolute bioavailability of eplerenone is unknown.
4-6 hours
* 43 to 90 L
* Apparent plasma cl=10 L/hr